

28-7-2014

To,
The Manager, Listing Department,
National Stock Exchange of India Limited
"Exchange Plaza"
Bandra-Kurla Complex,
Bandra – East,
Mumbai

Sub: Outcome of Board Meeting

Dear Sir,

With reference to the captioned matter, the exchange is hereby informed that the Board of Directors of Alembic Pharmaceuticals Ltd. at its meeting held today has inter alia taken following decisions:

1. Approval of Unaudited Financial Results for the quarter ended 30th June, 2014.
2. Designation of Mr. R. K. Baheti, Director-Finance & Company Secretary of the Company as Director-Finance & Chief Financial Officer of the Company w.e.f. 28th July, 2014.
3. Designation of Mr. Ajay Kumar Desai, Associate Vice President-Finance of the Company as Associate Vice President-Finance & Company Secretary and Compliance Officer of the Company w.e.f. 28th July, 2014.

In this regard, the Unaudited Financial Results of the Company for the quarter ended 30th June, 2014 alongwith Limited Review Report and a press release dated 28th July, 2014 are enclosed herewith.

Kindly take the same on your record.

Thanking you,
For **Alembic Pharmaceuticals Limited**

A. K. Desai

Ajay Kumar Desai
AVP-Finance & Company Secretary

Encl.: A/a

CIN:L24230GJ2010PLC061123

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003, INDIA • TEL : (0265) 2280550, 2280880 • FAX : (0265) 2282506
Website : www.alembic-india.com • E-mail : alembic@alembic.co.in

28-7-2014

To,
The Manager,
Department of Corporate Services,
Bombay Stock Exchange Limited
P. J. Towers, Dalal Street,
Fort, Mumbai

Sub: Outcome of Board Meeting

Dear Sir,

With reference to the captioned matter, the exchange is hereby informed that the Board of Directors of Alembic Pharmaceuticals Ltd. at its meeting held today has inter alia taken following decisions:

1. Approval of Unaudited Financial Results for the quarter ended 30th June, 2014.
2. Designation of Mr. R. K. Baheti, Director-Finance & Company Secretary of the Company as Director-Finance & Chief Financial Officer of the Company w.e.f. 28th July, 2014.
3. Designation of Mr. Ajay Kumar Desai, Associate Vice President-Finance of the Company as Associate Vice President-Finance & Company Secretary and Compliance Officer of the Company w.e.f. 28th July, 2014.

In this regard, the Unaudited Financial Results of the Company for the quarter ended 30th June, 2014 alongwith Limited Review Report and a press release dated 28th July, 2014 are enclosed herewith.

Kindly take the same on your record.

Thanking you,
For **Alembic Pharmaceuticals Limited**

A. K. Desai

Ajay Kumar Desai
AVP-Finance & Company Secretary

Encl.: A/a

CIN:L24230GJ2010PLC061123

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003, INDIA • TEL : (0265) 2280550, 2280880 • FAX : (0265) 2282506
Website : www.alembic-india.com • E-mail : alembic@alembic.co.in

F-7 Laxmi Mills
Shakti Mills Lane (Off Dr E Moses Rd)
Mahalaxmi Mumbai 400 011 India
Tel : 91 22 2493 2502 / 6655 1770
Fax : 91 22 6655 1774
Grams : VERIFY
www.KSAiyar.com
Mail@KSAiyar.com

To,
The Board of Directors;
Alembic Pharmaceuticals Limited;
Alembic Road,
Vadodara 390 003.

RE: **LIMITED REVIEW OF THE UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE
QUARTER ENDED 30th June, 2014 PREPARED BY THE COMPANY.**

1. INTRODUCTION

We have reviewed the accompanying statement of unaudited consolidated financial results of **Alembic Pharmaceuticals Limited** for the quarter ended on **30th June, 2014** except for the disclosures regarding public shareholding and Promoter and Promoter Group shareholding which have been traced from disclosures made by the management, but have neither been reviewed nor been audited by us. This Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Management is responsible for the preparation and fair presentation of this interim financial information in accordance with Indian Generally Accepted Accounting Principles. Our responsibility is to issue a report on this Statement based on our review.


2. SCOPE OF REVIEW

- 2.1 We conducted our review in accordance with Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether this Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 2.2 We report that the consolidated unaudited financial results have been prepared by the Company's management in accordance with the requirements of Accounting Standard 21 – Consolidated Financial Statements and Accounting Standard 23 Accounting for Investments in Associates in Consolidated Financial Statements issued by the Central Government under Companies (Accounting Standards) Rules, 2006 on the basis of the separate unaudited consolidated financial results of its 100% Subsidiary i.e. Alembic Global Holding SA, Switzerland and an Associate which have not been reviewed.

3. CONCLUSION

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited consolidated financial results prepared in accordance with applicable accounting standards notified under the Companies Act 1956, which shall continue to apply in respect of section 133 of the Companies Act 2013 in terms of General Circular 15/2013 dated 13th September 2013 of the Ministry of Corporate Affairs and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For K.S.Aiyar & Co.
Chartered Accountants
FRN: 100186W



Rajesh S Joshi
Partner
M.No. 38526

Place: Vadodara
Date: 28th July, 2014

UNAUDITED FINANCIAL RESULTS

FOR THE PERIOD ENDED 30TH JUNE, 2014

Rs. in lacs

	Particulars	STANDALONE			
		Quarter Ended			Year Ended
		June-14	March-14	June-13	March-14
PART- I		(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	(a) Net Sales / Income from Operations				
	Domestic	27,840	24,536	24,120	104,106
	Exports	20,525	21,092	18,725	80,793
	Total	48,365	45,628	42,845	184,899
	Less : Excise Duty	248	189	218	771
	Net Sales / Income from Operations	48,117	45,439	42,627	184,128
	(b) Other Operating Income	63	70	57	251
	Total Income from Operations	48,180	45,509	42,684	184,379
2	Expenses				
	(a) Decrease/(increase) in stock in trade and work in progress	(2,677)	407	(1,303)	(4,065)
	(b) Consumption of Raw Materials & Packing Materials	14,728	13,088	13,597	55,593
	(c) Purchase of traded goods	5,646	4,128	4,949	19,807
	(d) Employees' Cost	7,322	6,677	5,636	24,446
	(e) Marketing Expense	4,954	2,934	4,378	16,075
	(f) Research and Development Expense	2,754	2,593	2,070	10,510
	(g) Excise Duty	152	62	79	425
	(h) Other Expenditure	5,972	6,955	5,849	25,686
	Total Expenses	38,851	36,844	35,255	148,477
3	Profit from Operations before Other Income, Interest, Depreciation & Exceptional Items	9,329	8,665	7,429	35,902
4	Other Income	18	277	2	319
5	Profit/(Loss) from Ordinary Activities before Interest, Depreciation, & Exceptional Items	9,347	8,942	7,431	36,221
6	Depreciation	1,071	1,099	953	4,049
7	Interest (Net)	56	229	147	981
8	CSR Expense	65	-	-	-
9	Net Profit from Ordinary Activities before Tax	8,155	7,614	6,331	31,191
10	Tax Expense				
	Less : Provision for Current Tax	1,714	1,752	1,327	6,700
	Less /Add : Provision for Deferred Tax Liability/(Assets)	293	148	57	663
11	Net Profit from Ordinary Activities after Tax	6,148	5,714	4,947	23,828
12	Paid up Equity Share Capital (Face value of share Rs. 2/-)	3,770	3,770	3,770	3,770
13	Reserves excluding Revaluation Reserve	-	-	-	59,199
14	Basic & Diluted EPS (Not Annualised)	3.26	3.03	2.62	12.64
PART- II					
A	Particulars of Shareholding				
1	Public Shareholding				
	- Number of Shares	48777294	48777294	48777294	48777294
	- Percentage of Shareholding	25.87	25.87	25.87	25.87
2	Promoters and Promoter Group Shareholding				
	- Fully Non - Encumbered				
	- Number of Shares	139738620	139738620	139738620	139738620
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00
	- Percentage of Shares (as a % of the total share capital of the Company)	74.13	74.13	74.13	74.13
B	INVESTOR COMPLAINTS	Quarter Ended on 30th June, 2014			
	Pending at the beginning of the quarter			NIL	
	Received during the quarter			5	
	Disposed of during the quarter			5	
	Remaining unresolved at the end of the quarter			NIL	



UNAUDITED FINANCIAL RESULTS
FOR THE PERIOD ENDED 30TH JUNE, 2014

Rs. in Lacs

	Particulars	CONSOLIDATED			
		Quarter Ended			Year Ended
		June-14	March-14	June-13	March-14
		(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
PART- I					
1	(a) Net Sales / Income from Operations				
	Domestic	27,840	24,536	24,120	104,106
	Exports	21,773	21,986	18,757	82,735
	Total	49,613	46,522	42,877	186,841
	Less : Excise Duty	248	189	218	771
	Net Sales / Income from Operations	49,365	46,333	42,659	186,070
	(b) Other Operating Income	63	70	57	251
	Total Income from Operations	49,428	46,403	42,716	186,321
2	Expenses				
	(a) Decrease/(increase) in stock in trade and work in progress	(2,677)	407	(1,303)	(4,065)
	(b) Consumption of Raw Materials & Packing Materials	14,728	13,088	13,597	55,593
	(c) Purchase of traded goods	5,646	4,128	4,949	19,807
	(d) Employees' Cost	7,561	6,715	5,636	24,700
	(e) Marketing Expense	5,196	3,088	4,378	16,618
	(f) Research and Development Expense	2,953	3,120	2,241	11,643
	(g) Excise Duty	152	62	79	425
	(h) Other Expenditure	6,202	6,666	5,991	25,829
	Total Expenses	39,761	37,274	35,568	150,550
3	Profit from Operations before Other Income, Interest, Depreciation & Exceptional Items	9,667	9,129	7,148	35,771
4	Other Income	18	277	2	319
5	Profit from Ordinary Activities before Interest, Depreciation, & Exceptional Items	9,685	9,406	7,150	36,090
6	Depreciation	1,071	1,099	953	4,049
7	Interest (Net)	56	229	147	981
8	CSR Expense	65	-	-	-
9	Net Profit from Ordinary Activities before Tax	8,493	8,078	6,050	31,060
10	Tax Expense				
	Less : Provision for Current Tax	1,735	1,801	1,329	6,847
	Less/(Add) : Provision for Deferred Tax Liability /(Assets)	293	148	57	663
11	Net Profit from Ordinary Activities after Tax	6,465	6,129	4,664	23,550
12	Share of Profit of Associates	2	-	-	-
13	Net Profit after Tax and share of profit of associates	6,467	6,129	4,664	23,550
14	Paid up Equity Share Capital	3,770	3,770	3,770	3,770
	(Face value of share ' 2/-)				
15	Reserves excluding Revaluation Reserve	-	-	-	63,787
16	Basic & Diluted EPS (Not Annualised)	3.43	3.25	2.47	12.49
PART- II					
A	Particulars of Shareholding				
1	Public Shareholding				
	- Number of Shares	48777294	48777294	48777294	48777294
	- Percentage of Shareholding	25.87	25.87	25.87	25.87
2	Promoters and Promoter Group Shareholding				
	- Fully Non - Encumbered				
	- Number of Shares	139738620	139738620	139738620	139738620
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00
	- Percentage of Shares (as a % of the total share capital of the Company)	74.13	74.13	74.13	74.13
B	INVESTOR COMPLAINTS	Quarter Ended on 30th June, 2014			
	Pending at the beginning of the quarter			NIL	
	Received during the quarter			5	
	Disposed of during the quarter			5	
	Remaining unresolved at the end of the quarter			NIL	



Notes :

- 1 The above results, have been duly reviewed by Statutory Auditors, recommended by the Audit Committee and approved by the Board of Directors. The Company has opted to publish consolidated financial results, pursuant to option made available as per clause 41 of the listing Agreement. The Standalone Financial Results are available on the company's website www.alembic-india.com.
- 2 The Company is engaged in Pharmaceuticals business only and therefore, there is only one reportable segment in accordance with the Accounting Standard on Segment Reporting (AS-17).
- 3 The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

Place : Vadodara

Date : 28th July, 2014



For Alembic Pharmaceuticals Limited


Chirayu Amin
Chairman and Managing Director

For Immediate Release
Alembic Pharmaceuticals Limited
Consolidated Results for Quarter ended 30.06.2014

Revenues up by 16% at Rs 496 crores
PBT up by 40% at Rs 85 crores

Editors Synopsis

Quarter ended 30th June 2014

- **Net sales up by 16% to Rs 496.1 crores against Rs 428.8 crores in the corresponding quarter last year**
- **Profit before tax up by 40% to Rs 84.9 crores against Rs 60.5 crores in the corresponding quarter last year**
- **Net profit after tax up by 39% to Rs 64.7 crores against Rs 46.6 crores in the corresponding quarter last year**
- **EBITDA margins is 19.5% at Rs 96.7 crores against 16.7% at Rs 71.5 crores in the corresponding quarter last year**
- **Domestic Branded formulations sales up 16% for the quarter at Rs. 223.3 crores against Rs. 192.0 crores in corresponding quarter last year.**
- **International Generic Formulations sales up 33% for the quarter at Rs. 113.8 crores against Rs. 85.5 crores in corresponding quarter last year**
- **3 ANDA application were filed for the quarter taking cumulative ANDA filings of the Company to 64**
- **3 ANDA approvals were received for the quarter taking cumulative ANDA/NDA approvals to 35 (including 5 tentative approvals)**

Vadodara, 28th July, 2014

Alembic Pharmaceuticals Limited reported a 16% increase in revenues to Rs 496.1 crores for the quarter ended 30th June 2014, compared to Rs 428.8 crores in the corresponding quarter last year.

The Company posted 40% growth in profit before tax at Rs. 84.9 crores for the quarter ended 30th June 2014 against Rs 60.5 crores posted in corresponding quarter last fiscal.

The net profit grew by 39% at Rs 64.7 crores for the quarter ended 30th June 2014 against Rs 46.6 crores in corresponding quarter last fiscal.

EBIDTA margins for quarter ended 30th June 2014 up at 19.5% to Rs 96.7 crores from 16.7% at Rs 71.5 crores for corresponding quarter last year.

India Branded Formulations Business

The India Branded formulations business posted sales of Rs. 223.3 crores against Rs. 192.0 crores with a 16% growth over the corresponding quarter of the previous year.

Specialty and Acute segments grew by 25% and 4% respectively in current quarter.

International Generics

International Generic Formulation posted growth of 33% and posted sales of Rs. 113.8 crores against Rs. 85.5 crores over the corresponding quarter last year.

During the quarter 3 ANDA applications were filed taking cumulative ANDA filings of the Company to 64. During the quarter 3 ANDA approvals were received taking cumulative ANDA/NDA approvals to 35 (including 5 tentative approvals).

Summary of Total Revenue is as under:

(Rs. in Lacs)

Particulars	Q1 FY15	Q1 FY14	% Change
Formulation			
India Branded	22328	19197	16%
India Generics	2522	2645	(-) 5%
International Branded	2268	1501	51%
International Generics	11381	8547	33%
API	10631	10697	(-) 1%
Export Incentives	483	290	-
Total	49613	42877	16%

The Profit break-up is as under:

(Rs. in Lacs)

Particulars	Q1 FY15	Q1 FY14	% Change
Operating Income	9667	7148	35%
Profit Before Tax	8493	6050	40%
Net Profit after Tax	6467	4664	39%

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities all over the world including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a marketing team of over 4400 are well recognized by doctors and patients.

Information about the company can be found at www.alembic-india.com; (reuters:ALEM.NS) (bloomberg:ALPM) (nse:APLLTD) (bse:533573)

For more information contact:

Alembic Pharmaceuticals Limited

Ajay Kumar Desai

Phone: +91 22 – 306 11681

Email: ajay.desai@alembic.co.in

Mitanshu Shah

Phone: +91 265 – 3007630

Email: mitanshu.shah@alembic.co.in